Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 93Small Cell Lung Carcinoma 74Neuroblastoma 44Carcinoma, Ovarian Epithelial 43Fallopian Tube Neoplasms 41Lung Neoplasms 39Neoplasms 29Uterine Cervical Neoplasms 26Leukemia 20Brain Neoplasms 18Leukemia, Myeloid, Acute 17Recurrence 16Sarcoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Neoplasm Metastasis 13Lymphoma 12Central Nervous System Neoplasms 12Retinoblastoma 11Glioma 11Carcinoma, Non-Small-Cell Lung 11Sarcoma, Ewing 10Unspecified Adult Solid Tumor, Protocol Specific 8Neuroectodermal Tumors, Primitive, Peripheral 8Myelodysplastic Syndromes 8Medulloblastoma 8Endometrial Neoplasms 8Burkitt Lymphoma 8Lymphoma, Follicular 7Leukemia, Myelomonocytic, Chronic 7Blast Crisis 7

Interventions

Nivolumab 20Ipilimumab 10Paclitaxel 7linrodostat 6Standard of Care 6Sirolimus 5Gemcitabine 5Bevacizumab 5temsirolimus 4relatlimab 4Pemetrexed 4Docetaxel 4Carboplatin 4ARRY-334543 4Vorinostat 3Erlotinib Hydrochloride 3Dasatinib 3Cetuximab 3regorafenib 2olaparib 2apatinib 2anlotinib 2abemaciclib 2Trastuzumab 2Surveys and Questionnaires 2Sunitinib 2Sorafenib 2Olanzapine 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Cancer × Topotecan × Clear all
NCT00770731 2013-02-13

Study of Temsirolimus, Topotecan, and Bortezomib

M.D. Anderson Cancer Center

Phase 1 Completed
80 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡